Bob, I would like to hear an update on the 45 in the information arm. That certainly should be something they could talk about at industry expert theater. I wonder if any are still living from the pseudoprogressors group. At this point I really think the journal and tld will have to wait some time longer but certainly interesting things that can be talked about on June 4th
Real, live, DCVax-treated patients at ASCO could also be powerful and create a buzz. It certainly was in 2018. It would be beneficial for oncologists to interact with these patients at Northwest Bio’s very large booth to learn about their personal experiences with the treatment as well.
Oh and by the way, the MHRA is quite interested in treatments that have taken a patient-centered approach like Northwest Bio has: